top of page


52North raises £3.2 million to bring finger-prick cancer test closer to patients
52North, a University of Cambridge spin-out and a company that Milltrust Ventures invested in 2022 via the Future Health Fund, has raised £3.2 million in an early-stage funding round to accelerate clinical validation, regulatory progression and the UK launch of its lead product, Neutrocheck — a rapid, finger-prick blood test built to catch one of chemotherapy's most dangerous complications before it becomes an emergency. A test built to ease pressure on emergency care Neutroc
2 min read
bottom of page
